Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Theriogenology ; 145: 138-143, 2020 Mar 15.
Article in English | MEDLINE | ID: mdl-31757482

ABSTRACT

The aim of the present study was to determine the recovery of embryonic structures (ova/embryos) and fertilization rate in superovulated buffaloes treated with PGF2α during the periovulatory period. On day 0 (D0), buffaloes at random stages of the estrous cycle were treated with an intravaginal progesterone device (P4; 1.0 g) and estradiol benzoate (EB, 2.0 mg i.m.). From D4 to D7, all buffaloes received i.m. FSH (200 mg total) twice-daily over 4 days in decreasing doses. On D6 and D7, the animals were given PGF2α analogue (0.53 mg i.m. sodium cloprostenol) and the P4 device was removed on D7. On D8, all buffaloes received GnRH (20 µg i.m. buserelin acetate). Buffaloes were then randomly allocated to one of three groups: control (Group C, n = 18), no further treatment; PGF2α analogue injection (Group IM-PGF; n = 18), four injections (0.53 mg i.m. sodium cloprostenol) 12 h apart, from D8 to D10; PGF2α analogue osmotic pump (Group OP-PGF; n = 18), s.c. osmotic mini-pump (2.12 mg sodium cloprostenol) from D8 to D10. The study had a crossover design (three treatments x three replicates). All animals underwent timed AI, 12 and 24 h after treatment with GnRH. Embryonic structures were recovered on D14. Ovarian ultrasonography was used on D8 and D14 to record follicular superstimulation and superovulatory responses. Blood samples were obtained on Days 7, 8, 9 and 10 to measure circulating concentrations of P4, E2 and PGFM. Data were analyzed by GLIMMIX procedure of SAS®. There was no effect (P = 0.58) of treatment on the total number of embryonic structures (Group C, 2.1 ±â€¯0.8; Group IM-PGF, 2.1 ±â€¯0.6; Group OP-PGF, 1.4 ±â€¯0.4). There was also no effect (P = 0.93) of treatment on the recovery rate of embryonic structures (oocytes and embryos D14/CL D14). The fertilization rate was higher (P = 0.04) in Groups IM-PGF (84.6%) and OP-PGF (88.0%), which did not differ, than Group C (63.2%). The viable embryos rate was greater (P < 0.01) for Groups IM-PGF (82.0%) and OP-PGF (88.0%) than Group C (52.6%). There was no interaction between treatment and time and treatment effects for P4, E2 and PGFM concentrations. The findings showed that treatment with PGF2α during the periovulatory period has potential to increase fertilization rate and embryo production in superovulated buffaloes.


Subject(s)
Buffaloes/physiology , Dinoprost/pharmacology , Animals , Dinoprost/analogs & derivatives , Dinoprost/blood , Estradiol/blood , Female , Fertility , Ovulation , Progesterone/blood
2.
Theriogenology ; 119: 275-281, 2018 Oct 01.
Article in English | MEDLINE | ID: mdl-30064074

ABSTRACT

This study aimed to compare the reproductive efficiency of dairy buffaloes subjected to TAI protocols based on progesterone, estrogen, and equine chorionic gonadotrophin (P4/E2+eCG) during the fall/winter (n = 168) and spring/summer (n = 183). Buffaloes received an intravaginal P4 device (1.0 g) plus estradiol benzoate (EB; 2.0 mg im) at a random stage of the estrous cycle (D-12). Nine days later (D-3), the P4 device was removed and buffaloes were given PGF2α (0.53 mg im sodium cloprostenol) plus eCG (400 IU im). GnRH (10 µg im buserelin acetate) was administered 48 h after P4 device removal (D-1). All animals were subjected to TAI 16 h after GnRH administration (D0). Frozen-thawed semen from one bull was used for all TAI, which were all performed by the same technician. Ultrasound examinations were performed on D-12 and D-3 to ascertain cyclicity (presence of CL), D-3 and D0 to measure the diameter of the dominant follicle (ØDF), D+10 to verify the ovulation rate and diameter of the corpus luteum (ØCL), and D+30 and D+45 to detect pregnancy rate (P/AI 30d and 45d, respectively) and embryonic mortality (EM). Fetal mortality (FM) was established between 45 days and birth, and pregnancy loss between 30 days and birth. There were significant differences between fall/winter and spring/summer only for cyclicity rate [76.2% (128/168) vs. 42.6% (78/183); P = 0.02]. The others variables did not differ between the seasons: ØDF on D-3 (9.6 ± 0.2 mm vs. 9.8 ± 0.2 mm; P = 0.35); ØDF on D0 (13.1 ± 0.2 mm vs. 13.2 ± 0.2 mm; P = 0.47); ovulation rate [86.9% (146/168) vs. 82.9% (152/182); P = 0.19]; ØCL on D+10 (19.0 ± 0.3 mm vs. 18.4 ± 0.3 mm, P = 0.20); P/AI on D+30 [66.7% (112/168) vs. 62.7% (111/177); P = 0.31]; P/AI on D+45 [64.8%% (107/165) vs. 60.2% (106/176); P = 0.37]; EM [1.8% (2/111) vs. 3.6% (4/110); P = 0.95]; FM [21.9% (18/82) vs. 8.0% (7/87); P = 0.13]; and PL [23.8% (20/84) vs. 12.1% (11/91); P = 0.13]. In conclusion, dairy buffaloes present similar reproductive efficiency in fall/winter and spring/summer when subjected to P4/E2/eCG-based protocol for TAI.


Subject(s)
Buffaloes , Chorionic Gonadotropin/pharmacology , Estradiol/analogs & derivatives , Estrus Synchronization/methods , Insemination, Artificial/veterinary , Progesterone/pharmacology , Animals , Estradiol/pharmacology , Female , Ovarian Follicle/drug effects , Pregnancy , Seasons
SELECTION OF CITATIONS
SEARCH DETAIL
...